Janus Henderson Group PLC Puma Biotechnology, Inc. Transaction History

Janus Henderson Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 31, 2019	SELL	$12.3 - $35.76 $26.7 Million - $77.6 Million	-2,170,423 Closed	0 $0
Q1 2019 Apr 30, 2019	BUY	$20.77 - $42.37 $6.41 Million - $13.1 Million	308,479 Added 16.57%	2,170,423 $84.2 Million
Q4 2018 Feb 06, 2019	SELL	$20.07 - $46.7 $5.71 Million - $13.3 Million	-284,516 Reduced 13.26%	1,861,944 $37.9 Million
Q3 2018 Nov 09, 2018	SELL	$41.2 - $59.85 $47.6 Million - $69.2 Million	-1,155,561 Reduced 35.0%	2,146,460 $98.4 Million
Q2 2018 Aug 10, 2018	SELL	$48.3 - $68.25 $57 Million - $80.6 Million	-1,180,285 Reduced 26.33%	3,302,021 $195 Million
Q1 2018 May 14, 2018	BUY	$59.7 - $99.25 $7.56 Million - $12.6 Million	126,663 Added 2.91%	4,482,306 $305 Million
Q4 2017 Feb 09, 2018	BUY	$93.85 - $132.45 $231 Million - $326 Million	2,464,742 Added 130.35%	4,355,643 $431 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $2.4 Million - $3.98 Million	33,270 Added 1.79%	1,890,901 $0
Q2 2017 Aug 17, 2017	BUY	N/A	1,857,631	1,857,631 $162 Million

102

29.1M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $132M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.